Back to Markets
Indices● Neutral
Cardiff Oncology Onvansertib Data: Next Catalyst for CRDF
Cardiff Oncology's updated Phase II slide deck for onvansertib defines the next catalyst path for CRDF stock in RAS-mutated mCRC. Here are the data points to watch.
Continue with
Cardiff Oncology (CRDF) published an updated slide deck for Phase II CRDF-004 on June 7, 2026. The presentation covers onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). For a small-cap biotech without a marketed product, this slide deck is the closest thing to a near-term binary catalyst. The data update refines the drug's efficacy and safety profile, defining the next step in the development timeline.
What the Updated Slide Deck Changes for the Onvansertib Timeline
The slide deck is not a press release with top-line results. It is an investor presentation that likely adds new patient cohorts, extends follow-up, or highlights specific efficacy metrics. In the context of a Phase II study, any meaningful update can shift the probability of regulatory success. The key question: does the updated data strengthen the case for a registrational Phase III trial, or does it leave ambiguity that delays a go/no-go decision?
Cardiff Oncology is developing onvansertib as a polo-like kinase 1 (PLK1) inhibitor. PLK1 is overexpressed in many cancers and linked to poor prognosis. The CRDF-004 trial tests onvansertib in combination with FOLFIRI and bevacizumab against chemotherapy alone in first-line RAS-mutated mCRC. The design targets a population with limited targeted options.
Why RAS-Mutated mCRC Is a High-Unmet-Need Indication
Approximately 40% to 50% of mCRC patients carry a RAS mutation. That genetic status renders them ineligible for EGFR inhibitors such as cetuximab. Standard first-line therapy remains chemotherapy plus a VEGF inhibitor like bevacizumab. Outcomes are poor: median progression-free survival (PFS) in historical controls is about 10 to 12 months, with limited improvement from newer combinations. A drug that meaningfully improves objective response rate (ORR) or PFS in this population would fill a defined clinical gap.
The RAS-mutated subset is one of the most challenging segments in colorectal cancer drug development. Several targeted agents have failed in late-stage trials. Onvansertib targets a different pathway – cell cycle regulation via PLK1 – rather than the MAPK pathway directly affected by RAS mutations. This mechanism may offer synergy with chemotherapy without overlapping resistance mechanisms.